CervoMed Stock Price, News & Analysis

CervoMed (NASDAQ: CRVO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company highlighted positive 16-week results from the extension phase of their Phase 2b RewinD-LB trial for neflamapimod in treating dementia with Lewy bodies (DLB). The trial showed significant improvements in clinical progression measures, with plans to initiate Phase 3 trials in mid-2026. The company ended Q1 with $35.2 million in cash, down from $38.9 million in December 2024. Financial results showed grant revenue of $1.9 million, R&D expenses of $4.8 million (up from $2.8 million), and a net loss of $4.9 million (increased from $2.5 million). CervoMed is also expanding its drug development pipeline with new Phase 2a trials for primary progressive aphasia and ischemic stroke recovery.

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.

Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.

CervoMed Inc. (NASDAQ: CRVO) announced positive results from the Extension phase of their Phase 2b RewinD-LB study of neflamapimod for treating dementia with Lewy bodies (DLB). The study showed that neflamapimod, when administered with New Capsules achieving target plasma concentrations, significantly slowed clinical progression compared to controls.

Key findings include:

• Improvement in Clinical Dementia Rating Sum of Boxes (CDR-SB) with New Capsules vs Old Capsules (p<0.001) and vs placebo (p=0.003)
• Mean improvement of 0.73 points with New Capsules compared to Old Capsules
• 40% lower rate of clinical worsening in New Capsule recipients
• Improved outcomes in Alzheimer's Disease Cooperative Study (ADCS-CGIC)
• Reduced incidence of falls (4% vs 15.2%) with New Capsules

The results will be presented at the AD/PD™ 2025 conference on April 5, 2025, demonstrating proof-of-concept for neflamapimod as a DLB treatment.

CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced an upcoming oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AP/PD™) in Vienna, Austria on April 5, 2025.

The presentation will focus on detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). The presentation will be delivered by CEO John Alam, MD, and Stephen Gomperts, MD, PhD, from Harvard Medical School and Massachusetts General Hospital.

CervoMed (NASDAQ: CRVO) has reported its Q4 and full-year 2024 financial results, highlighting positive 16-week results from the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). The trial showed significant improvements in the primary outcome measure.

Financial highlights include:

• Cash position of $38.9 million as of December 31, 2024 (up from $7.8M in 2023)
• Grant revenue of $9.7 million for 2024 (up from $7.1M in 2023)
• R&D expenses increased to $18.8 million (from $8.4M in 2023)
• Net loss of $16.3 million for 2024

The company plans to initiate a Phase 3 trial in mid-2026 and expects to report 32-week extension phase results in H2 2025. Current cash runway extends into mid-2026.

CervoMed (NASDAQ: CRVO) has announced positive results from the 16-week extension phase of its Phase 2b RewinD-LB study for neflamapimod in treating dementia with Lewy bodies (DLB). The new batch of drug capsules showed significant improvements compared to both old capsules and placebo:

Key findings include:

• Improved Clinical Dementia Rating Sum of Boxes (CDR-SB) scores (p<0.001 vs. old capsules; p=0.003 vs. placebo)
• Better performance on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (p=0.035)
• Lower incidence of falls (7.4% vs. 14.5% for old capsules)
• Higher plasma drug concentrations (5.1 vs. 4.0 ng/mL, p=0.03)

The study involved 149 participants, with 94 receiving the new capsules and 55 receiving old capsules. The results suggest neflamapimod's potential to fundamentally change DLB treatment, particularly significant as no FDA-approved drugs currently exist for DLB management in the U.S.

CervoMed (NASDAQ: CRVO) provided an update on its neflamapimod development program for dementia with Lewy bodies (DLB) at the 8th International Lewy Body Dementia Conference. The Phase 2b RewinD-LB trial's blinded portion showed no significant differences between neflamapimod 40mg (three times daily) and placebo groups.

The company identified that lower-than-expected bioavailability may be related to the age of the drug batch used during the double-blind phase. However, newer capsules tested in Q4 2024 achieved targeted plasma concentrations in both a food effect study and in 13 participants during the open-label extension (OLE) phase.

Topline data from the first 16 weeks of the OLE phase, including participants receiving the newer capsules, is expected in Q1 2025. This data will include various efficacy endpoints and pharmacokinetic data, which will guide future development decisions.

CervoMed (NASDAQ: CRVO) has announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference (ILBDC) in Amsterdam on January 31, 2025. The study focuses on neflamapimod treatment for dementia with Lewy bodies (DLB).

The presentation, titled 'Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB),' will be delivered by Dr. John Alam, CEO and Co-Principal Investigator of the study, during Symposium VIII-Therapy at 13:30 CET / 7:30 ET. The initial topline results were previously disclosed on December 10, 2024.

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, has granted equity awards to two new employees. The company awarded options to purchase a total of 14,753 shares of common stock, with an exercise price of $11.91 per share, matching the closing price on December 6, 2024. These options will vest over three years in 36 equal monthly installments, contingent on continued employment. The grants were approved by the Compensation Committee as inducement awards under Nasdaq Listing Rule 5635(c)(4).